Company Overview of Sigma Tau Pharmasource, Inc.
Sigma Tau Pharmasource, Inc., a biopharmaceutical contract manufacturer, offers injectable formulations. It provides tangential flow filtration and high pressure extrusion services, as well as dual chamber vials. Sigma Tau Pharmasource also offers CYSTARAN (cysteamine ophthalmic solution), a topical ophthalmic therapeutic for the treatment of patients suffering from corneal cystine crystal accumulation as a result of cystinosis. The company was formerly known as Klee Pharmaceuticals Inc. and changed its name to Sigma Tau Pharmasource, Inc. in February 2010. Sigma Tau Pharmasource, Inc. was incorporated in 2009 and is based in Indianapolis, Indiana.
6925 Guion Road
Indianapolis, IN 46268
Founded in 2009
Key Executives for Sigma Tau Pharmasource, Inc.
Vice President of Commercial Operations
Compensation as of Fiscal Year 2014.
Sigma Tau Pharmasource, Inc. Key Developments
Sigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206
Feb 4 14
Sigma-Tau Pharmaceuticals, Inc. announced that the first patient has been dosed as part of the company's Phase I/II multi center, double blind, randomized, placebo controlled clinical trial for STP206, in development for the prevention of necrotizing enterocolitis (NEC) in very low birth weight premature infants. STP206 is a live biotherapeutic being developed in the United States, under an FDA investigational new drug application (IND). NEC is the most common serious acquired disease of the gastrointestinal tract in preterm infants, most often affecting infants under 1,500 g (3 lbs, 5 oz). The disease is characterized by signs of abdominal distension, intra-abdominal inflammation, and radiologic presence of pneumatosis intestinalis and/or portal venous air or free air indicating perforation of the bowel, which in the most severe cases, can be life threatening. The disease has been reported to occur in approximately 10% of very low birth weight (<=1500 g) infants and about 1 in every 2,000-4,000 births. There is presently no FDA approved treatment for NEC, resulting in an urgent, unmet medical need.
Sigma Tau Pharmasource, Inc. to Supply Pulmaquin to Aradigm Corporation
Sep 17 13
Sigma-Tau PharmaSource Inc. announced the launch of a broad manufacturing services agreement to provide clinical and commercial supplies of Pulmaquin to Aradigm Corporation. As part of the agreement, Sigma-Tau PharmaSource will manufacture all product for Aradigm's Phase 3 clinical studies, and will support Aradigm in the preparation of its submissions to regulatory authorities in pursuit of marketing approval for the product.
Sigma Tau Pharmasource, Inc. Names Jeff Hackman as New Vice President of Commercial Operations
Oct 29 12
Sigma Tau Pharmasource, Inc. announced the appointment of Jeff Hackman as its new Vice President of Commercial Operations. Mr. Hackman has joined the leadership team at Sigma-Tau Pharmaceuticals Inc.'s U.S. corporate headquarters, in Gaithersburg, Maryland. Most recently, at Intercell AG, Mr. Hackman served as the Chief Executive Officer of the U.S. office and Global Senior Vice President, Commercial Operations. Prior to this role, he held the position of Vice President, Global Marketing and Sales at Emergent Biosolutions.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|